NCT00920257View on ClinicalTrials.gov

A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

June 16, 2009

Primary Completion Date

April 17, 2013

Study Completion Date

April 17, 2013

Conditions
Cancer
Interventions
DRUG

GSK2141795

GSK2141795 is an oral AKT inhibitor.

Trial Locations (7)

10021

GSK Investigational Site, New York

37203

GSK Investigational Site, Nashville

73104

GSK Investigational Site, Oklahoma City

77030

GSK Investigational Site, Houston

21231-2410

GSK Investigational Site, Baltimore

02115

GSK Investigational Site, Boston

M5G 2M9

GSK Investigational Site, Toronto

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY